The University of Helsinki is an international scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international univer-sities in the world.
The Faculty of Medicine promotes scientific research of a high standard and is responsible for providing research-based undergraduate and postgraduate education in medicine, dentistry, psychology and logo-pedics, as well as for the English-language Master’s Programme in Translational Medicine. In addition to its teaching and research activities, the Faculty serves as a significant expert organisation in the healthcare sector and contributes to the discourse on ethics in the field. In terms of research, the Faculty aims for a place among the best medical faculties in the world, while consolidating and strengthening its status as a top-level institution of medical education.
Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.
Research Programs Unit (RPU) of the Faculty of Medicine, University of Helsinki (https://www.helsinki.fi/en/faculty-of-medicine/research-programs-unit) consolidates demonstrated research excellence, with focused research programs addressing the greatest challenges in human health. Research programs provide the critical mass to combine biomedical, translational and clinical research, forming a synergistic platform for top-class scientific and translational discoveries. Nine research programs com-prise of 89 research groups in total.
POSTDOCTORAL RESEARCHER POSITION
is available in the group of ERC grantee Dr. Pipsa Saharinen in the Translational Cancer Medicine Program.
We are looking for a highly motivated individual with a commitment to excellence and with the capability to work independently and as a part of a dynamic and collaborative research group.
A PhD degree in Life or Biomedical sciences, or an MD PhD degree, as well as excellent communication skills in spoken and written English, are required. Applicants with a strong background in vascular/cancer biology, imaging, mouse genetics, or cell/molecular biology are encouraged to apply.
We provide an international and stimulating work environment within a multidisciplinary research team. The research projects are focused on fundamental aspects of vascular biology with translational goals in vas-cular diseases, including cancer and severe inflammation (www.helsinki.fi/saharinenlab). The projects will be discussed in detail during the interview process of selected candidates. The successful applicant will use a wide range of state-of-the art technologies, coordinated by the University of Helsinki HiLIFE core facilities (https://www.helsinki.fi/en/helsinki-institute-of-life-science/hilife-res...).
We provide opportunities to develop both transferable and scientific skills, with strong support from your laboratory colleagues, and competitive salary. The Postdoctoral researcher salary is comprised of two separate parts; the job requirement component (here, level 5) and the personal performance component based on previous qualifications, experience and personal work performance, as per defined in the Gen-eral Collective Agreement for Finnish Universities.
The application, together with the required attachments, must be submitted through the University of Hel-sinki electronic recruitment system by clicking the Apply for job -link. Internal applicants (i.e. current em-ployees of the University of Helsinki) must submit their applications through the SAP HR portal.
The application should include a cover letter describing previous achievements and motivation for the po-sition (1 page), CV, track record of peer-reviewed publications, and names and contact details of two to three referees.
Apply by 10.4.2019.
The position will be filled once a suitable candidate has been identified. The initial appointment is for one year starting as soon as possible, with the possibility of extension. A six-month trial period will be ap-plied.
Further information is available from pipsa.saharinen(at)helsinki.fi, tel. +358-50-4486361.
Hakanpaa et al., Targeting beta1-integrin inhibits vascular leakage in endotoxemia. Proc Natl Acad Sci USA. 115:E6467-E6476, 2018.
Korhonen E, Lampinen A et al. Tie1 controls angiopoietin function in vascular remodeling and inflamma-tion. J Clin Invest. 126: 3495-3510, 2016.
Hakanpaa et al. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nature Commun 6: 5962, 2015.
Saharinen et al., Therapeutic targeting of the angiopoietin–TIE pathway. Nat. Rev. Drug. Disc. 16:635-661, 2017.
Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signaling in the cardiovascular and lymphatic systems. Clin. Science. 1:87-103, 2017.
10.04.2019 23:59 EESTContinue reading